title: Comparison of once-daily cephalosporin regimens for community-acquired lower respiratory tract infections in patients with chronic lung disease.
abstract: The efficacy of cefonicid and of ceftriaxone, administered once daily for the treatment of lower respiratory tract bacterial infections (pneumonia or bronchitis), was evaluated and compared in 118 patients with chronic lung disease. The patients were randomly assigned to receive 1 gm of either drug, intravenously or intramuscularly, daily for three to 11 days (mean, seven days). Pathogenic bacteria were isolated from sputum in 59% of patients; Haemophilus influenzae and Streptococcus pneumoniae predominated. Clinical cure or improvement was noted in 95% and 93% of patients treated with cefonicid and ceftriaxone, respectively, and bacteriologic cure or improvement in 69% and 81% (the differences were not significant). Side effects were infrequent and similar in the two treatment groups, except that diarrhea was more common in the ceftriaxone group (11%, versus 4.4% in the cefonicid group). It is concluded that patients with chronic lung disease who experience acute exacerbations associated with infection caused by H influenzae or S pneumoniae, or other susceptible organisms, can be effectively treated with once-daily administration of either cefonicid or ceftriaxone.
authors.affiliation: Veterans Administration Medical Center, Martinez, California.
authors.forename: R E
authors.initials: RE
authors.lastname: McCabe
authors.forename: D
authors.initials: D
authors.lastname: Schlossberg
authors.forename: G R
authors.initials: GR
authors.lastname: Donowitz
authors.forename: W M
authors.initials: WM
authors.lastname: Scheld
authors.forename: S R
authors.initials: SR
authors.lastname: Zellner
authors.forename: L B
authors.initials: LB
authors.lastname: Lindenberg
authors.forename: J H
authors.initials: JH
authors.lastname: Armstrong
authors.forename: M E
authors.initials: ME
authors.lastname: Ein
mesh_terms: D000328:Adult; D000368:Aged; D001991:Bronchitis / Q000188:drug therapy / Q000382:microbiology; D002435:Cefamandole / Q000031:analogs & derivatives / Q000627:therapeutic use; D015790:Cefonicid; D002443:Ceftriaxone / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy / Q000382:microbiology; D011446:Prospective Studies; D011897:Random Allocation; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D002511:Cephalosporins; D002435:Cefamandole; D015790:Cefonicid; D002443:Ceftriaxone